Competing/conflicts of interest: No stated conflict of interest.
Longitudinal effect of topical antiglaucoma medications on central corneal thickness
Article first published online: 5 JUN 2013
© 2012 The Authors. Clinical and Experimental Ophthalmology © 2012 Royal Australian and New Zealand College of Ophthalmologists
Clinical & Experimental Ophthalmology
Volume 41, Issue 4, pages 348–354, May/June 2013
How to Cite
Viswanathan, D., Goldberg, I. and Graham, S. L. (2013), Longitudinal effect of topical antiglaucoma medications on central corneal thickness. Clinical & Experimental Ophthalmology, 41: 348–354. doi: 10.1111/j.1442-9071.2012.02870.x
Funding sources: No stated funding sources.
- Issue published online: 5 JUN 2013
- Article first published online: 5 JUN 2013
- Accepted manuscript online: 7 SEP 2012 06:47AM EST
- Manuscript Accepted: 17 AUG 2012
- Manuscript Received: 20 APR 2012
- central corneal thickness;
- antiglaucoma medications;
- intraocular pressure
To determine the change in central corneal thickness over time and whether the use of long-term topical antiglaucoma medications influences central corneal thickness.
Case control study with retrospective and prospective data collection.
One hundred eighty-seven eyes of 187 glaucoma patients (mean follow up 6.92 ± 1.67 years) being treated with topical antiglaucoma medications (at least 3 years) with no history of surgery or laser were included and compared with 100 eyes of 100 age–matched, untreated control subjects (mean follow up 6.58 ± 1.93 years) who were glaucoma suspects with normal intraocular pressure not on any treatment.
Demographic data, central corneal thickness and intraocular pressure were collected at initial glaucoma diagnosis and at most recent visit, and findings were compared between two groups.
Main Outcome Measures
Mean change in central corneal thickness in microns (μm).
Central corneal thickness fell significantly (P < 0.0001) in treated eyes but not in control eyes (P = 0.18); mean central corneal thickness reduction was 12.29 ± 13.65 μm in treated eyes and 1.17 ± 8.75 μm in controls. Among treated eyes, central corneal thickness reduction was significant (P < 0.0001) in those treated with either prostaglandins or a combination of prostaglandin and beta-blockers, while no significant reduction occurred in eyes treated with only beta-blockers (P = 0.15) when compared with control eyes.
Prostaglandins appear to be associated with a small but significant central corneal thickness reduction over time. Serial central corneal thickness measurements might be helpful in glaucoma patients, particularly those on prostaglandins.